Episode Details
Back to Episodes
Daily Roundup | GSK Wins First Lung Cancer Approval — Jideytro Validates a $10.6B Bet
Published 1 day, 17 hours ago
Description
GSK's Jideytro cleared the FDA two months early — a week after the $10.6B Nuvalent deal closed — for GSK's first lung cancer approval. Plus Arrowhead's plozasiran (Redemplo) posts best-case triglyceride and pancreatitis data against Ionis's Tryngolza, Summit's ivonescimab two-year NSCLC survival ahead of its November decision, Celldex's Phase 2 failure in prurigo nodularis, Sanofi's FDA untitled letter over Beyfortus and Pfizer's RSV vaccine, and Trump's 200% generic tariff countdown.
Visit us at thepharmacloseout.com.